Watch and listen to CML topics featuring experts, patients, and more
Watch an informative series exploring common misperceptions in CML
Despite advancements from TKIs in the last 20 years, some patients still struggle with CML due to adverse events and intolerance. This video discusses how to potentially optimize treatment and move one step closer to solving CML for more patients.
This video discusses the various reasons why patients don’t always relate their true experiences with CML medications. Once aware of this communication gap, HCPs can make better assessments to help close the gap and potentially improve compliance.
Get different perspectives from patients with CML
4 min 28 sec watch
See what patients in later lines have to say about their experience with CML, including challenges they faced, how they overcame them, and what advice they have to share.
Hear what the experts have to say
Conversations in Care: Establishing Good Rapport
5 min watch
Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, discuss how to manage a patient with CML on their second TKI who may not be communicating their tolerability issues with their health care team.
Conversations in Care: Considering Switching Treatments
4 min 17 sec watch
Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, review possible next steps when a patient with CML on an effective second TKI wants to switch therapies due to a side effect that may be manageable.
Conversations in Care: Diving Deeper
4 min 56 sec watch
Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, consider solutions for a patient with CML who may be undermining their TKI therapy by treating a comorbidity with an over-the-counter drug that reduces TKI efficacy.
How Do You Monitor TKI Tolerability Issues Among Patients Receiving TKIs?
1 min 5 sec watch
Moshe Talpaz, MD, describes the importance of a strong team and early action for monitoring TKI tolerability issues among his patients receiving TKIs.
How Does Intolerance Impact Clinical Decisions?
39 sec watch
Javier Pinilla-Ibarz, MD, PhD, discusses how intolerance to TKIs impact clinical decisions in later lines of therapy for CML-CP compared to earlier lines of therapy.
Missing the Mark in CML
7 min 15 sec watch
Moshe Talpaz, MD, and Eri Matsuki, MD, discuss tolerability issues in later lines of CML and when a treatment switch may be necessary.
8 min 3 sec watch
Jorge Cortes, MD, and Carla Boquimpani, MD, analyze the consequences of treatment resistance in later lines of CML.
Choosing What to Change in CML
7 min 12 sec watch
Valentin Garcia Gutierrez, MD, PhD, and Gabriela Hobbs, MD, review case studies and discuss different management strategies for patients experiencing TKI intolerance.
FAQ: What Is the Most Common HCP Question About CML?
58 sec watch
Jorge Cortes, MD, discusses the most common question HCPs ask him: "When a patient with CML is resistant to treatment, what do I do next?"
FAQ: Is Switching Due to Low-Grade AEs Appropriate?
1 min 7 sec watch
Moshe Talpaz, MD, talks about the importance of considering low-grade AEs when it comes to treating patients in later lines of CML.
FAQ: Dose Adjustment or Switch?
1 min 18 sec watch
Jorge Cortes, MD, discusses how to approach different clinical scenarios for patients in later lines of therapy for CML.
The views and opinions expressed in these videos are solely those of the speakers. These videos are not intended to, and do not serve as medical advice, guidance, or recommendations from Novartis Pharmaceuticals Corporation.Back to top
Highlights from the CML Expert Perspectives podcast series
|Thomas LeBlanc and Kendra Sweet: Intolerance
|Thomas LeBlanc and Kendra Sweet: Intolerance and Resistance
The views and opinions expressed in these podcasts are solely those of the speakers. These podcasts are not intended to, and do not serve as medical advice, guidance, or recommendations from Novartis Pharmaceuticals Corporation.
AEs, adverse events; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.Back to top